This Stroke is the third leading cause of death globally after cardiovascular disease and cancer. The highest death rate in Indonesia is caused by stroke (21.2%), and data from the Indonesian Ministry of Health reports that stroke is the highest cause of death in Indonesia, which is 51%. Stroke patients who are hospitalized generally experience drug- related problems (DRPs), especially patients with complications and comorbidities. This study aims to determine the types of DRPs and the relationship between DRPs and Clinical Outcomes in ischemic stroke patients in the inpatient neurology ward of RSUP Dr. M. Djamil Padang. This study is an observational study using a descriptive crosssectional design, conducted by collecting data on ischemic stroke patients prospectively during the period May – July 2019. Data analysis used statistics using parametric test methods (T- Test and One Way Annova) and nonparametric test methods (Mann U Whitney and Kruskal Wallis Test). It was found that the most used drugs in stroke patients were antihypertensive drugs; amlodipine (class Ca Chanel Blocker) and candesartan (class Angiotensin Receptor Blocker), antiplatelet drugs; aspirin, H2 antagonist drugs; ranitidine, an antibacterial drug; ceftriaxone, a mucolytic drug; N – acetylcysteine and body fluids; stranger. For the types of Drug-Related Problems, namely drugs without indications at 14.29%, indications that are not treated by 59.52%, inappropriate drug selection by 16.47 %, excess doses by 0%, under doses by 2.38%, side effect reactions are 0%, drug interactions are 7.14%, and failure to receive drugs is 0%. From the results of statistical tests, it was found that there was a relationship between Drug- Related Problems in the inappropriate drug category and drug interactions with Clinical Outcomes of patients with systolic blood pressure. Then, there was a relationship between DrugRelated Problems in the category of drugs without the Clinical Outcomes score of patients with the Glasgow Coma Scale.

Keywords : Clinical Outcomes; DRPs; Ischemic Stroke; Ischemic Stroke Therapy).